Abstract:

Hepatitis B virus (HBV) infection is a global public health problem, which causes chronic hepatitis B, cirrhosis and hepatocellular carcinoma. At present, antiviral drugs for HBV can be classified into two types: interferon and nucleoside analogues; the later plays a role in suppressing viral replication by acting on the virus gene activity area, but it easily causes drug resistance mutations in HBV polymerase gene and eventually leads to treatment failure. Despite the progress in HBV treatment, how to achieve durable viral suppression has always remains a major clinical challenge. Therefore, early and rapid detection methods are important for finding drug-resistance mutations, so as to reduce the risk of liver-related morbidity and mortality, thus optimize the management of Chronic HBV infection.

Key words: Hepatitis B, Nucleoside analogues, Drug resistance mutations